VIDEO: ACP shown to have good efficacy, safety in geographic atrophy
SAN DIEGO — Results from the GATHER1 and GATHER2 studies showed a decrease in geographic atrophy progression in patients treated with avacincaptad pegol, or ACP, according to a study presented at Academy 2022.
Mohammad Rafieetary, OD, FAAO, who practices at the Charles Retina Institute, told Healio there is no current treatment for geographic atrophy, which is a stage of advanced dry age-related macular degeneration.
“There’s an unmet need for patients who lose eyesight through this progressive, irreversible disease,” he said.
Nearly 300 patients in the GATHER1 and GATHER2 studies received monthly intravitreal injections of ACP, which is an investigational complement C5 inhibitor, for 12 months.
“In both of these studies, the patients who received the agent had lesser amount of geographic atrophy progression,” Rafieetary said. “For GATHER1 it was 35% less, and for GATHER2 it was 17% less. Part of that difference may have been that GATHER2 allowed patients outside of the U.S., and it was a larger cohort.”
Rafieetary concluded: “Both of these studies showed good efficacy and good safety. [Neither] of the studies have patients with endophthalmitis or intraocular inflammation.”
Collapse
Rafieetary M. Avacincaptad pegol for geographic atrophy: A review of the GATHER1 And GATHER2 clinical trials. Presented at: Academy; Oct. 26-29, 2022; San Diego.
Read more about